Remove Heart Failure Remove Heart Transplant Remove Reimbursement
article thumbnail

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

DAIC

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP Heart Failure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,

CMS 111
article thumbnail

Endotronix Receives FDA Premarket Approval of the Cordella PA Sensor System for the Treatment of Heart Failure

DAIC

a privately held company dedicated to advancing the treatment of heart failure ( HF ) at the intersection of digital health and medtech, today announced Premarket Approval (PMA) from the U.S Reimbursement for implantation and ongoing management through existing reimbursement pathways. "At